

## Technology Advisory Interests Register

**Topic: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Ramesh Bulusu	Expert	Indirect - financial	I have been on the advisory board and received remuneration for expert advice from Deciphera pharmaceuticals. 2022-2024	27/05/2025	It was agreed that Dr Bulusu's declaration would not prevent them from providing expert advice to the committee